XML 33 R23.htm IDEA: XBRL DOCUMENT
v3.23.1

FINANCIAL INSTRUMENTS (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2023
Investments, All Other Investments [Abstract] |
SCHEDULE OF CASH AND CASH EQUIVALENTS AND INVESTMENTS | SCHEDULE OF CASH AND CASH EQUIVALENTS AND INVESTMENTS
|  | As of March 31, 2023 |
|  | Cost |  |  | Unrealized Gain (Loss) |  |  | Fair Value |  |  | Cash and Cash Equivalents |  |  | Investments |
Cash |  | $ | 1,370,129 |  |  | $ | - |  |  |  |  |  |  | $ | 1,370,129 |  |  |  |  |
Level 1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money market funds |  |  | 4,677,872 |  |  |  | - |  |  | $ | 4,677,872 |  |  |  | 4,677,872 |  |  |  |  |
Total cash and cash equivalents |  | $ | 6,048,001 |  |  | $ | - |  |  | $ | 4,677,872 |  |  | $ | 6,048,001 |  |  |  |  |
Level 1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investments |  | $ | 250,892 |  |  | $ | (3,381 | ) |  | $ | 247,511 |  |  |  |  |  |  | $ | 247,511 |
|  | As of June 30, 2022 |
|  | Cost |  |  | Unrealized Gain (Loss) |  |  | Fair Value |  |  | Cash and Cash Equivalents |  |  | Investments |
Cash |  | $ | 1,233,608 |  |  | $ | - |  |  |  |  |  |  | $ | 1,233,608 |  |  |  |  |
Level 1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money market funds |  |  | 15,016,058 |  |  |  | - |  |  | $ | 15,016,058 |  |  |  | 15,016,058 |  |  |  |  |
Total cash and cash equivalents |  | $ | 16,249,666 |  |  | $ | - |  |  | $ | 15,016,058 |  |  | $ | 16,249,666 |  |  |  |  |
Level 1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investments |  | $ | 245,187 |  |  | $ | (5,873 | ) |  | $ | 239,314 |  |  |  |  |  |  | $ | 239,314 |
SCHEDULE OF FAIR VALUE OF CONTINGENT CONSIDERATION | As of March 31, 2023, the Company’s contingent consideration liabilities current and non-current balances were as follows: SCHEDULE OF FAIR VALUE OF CONTINGENT CONSIDERATION
|  | As of March 31, 2023 |
|  | Contingent Consideration at Purchase Date |  |  | Consideration Paid |  |  | Changes in Fair Value |  |  | Fair Value |  |  | Contingent Consideration |
Level 3: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, current - S5D |  | $ | 2,060,300 |  |  | $ | (623,300 | ) |  | $ | 1,535,500 |  |  | $ | 2,972,500 |  |  | $ | 2,972,500 |
Contingent consideration, current - BLI |  |  | 1,841,100 |  |  |  | - |  |  |  | (823,900 | ) |  |  | 1,017,200 |  |  |  | 1,017,200 |
Contingent consideration, current - XRT |  |  | - |  |  |  | (197,498 | ) |  |  | 331,786 |  |  |  | 134,288 |  |  |  | 134,288 |
Total contingent consideration, current portion |  | $ | 3,901,400 |  |  | $ | (820,798 | ) |  | $ | 1,043,386 |  |  | $ | 4,123,988 |  |  | $ | 4,123,988 |
Level 3: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, non-current - S5D |  | $ | 7,108,900 |  |  | $ | (735,701 | ) |  | $ | (3,770,799 | ) |  | $ | 2,602,400 |  |  | $ | 2,602,400 |
Contingent consideration, non-current - BLI |  |  | 4,297,900 |  |  |  | - |  |  |  | (380,500 | ) |  |  | 3,917,400 |  |  |  | 3,917,400 |
Total contingent consideration, net of current portion |  | $ | 11,406,800 |  |  | $ | (735,701 | ) |  | $ | (4,151,299 | ) |  | $ | 6,519,800 |  |  | $ | 6,519,800 |
As of June 30, 2022, the Company’s contingent consideration liabilities current and non-current balances were as follows:
|  | As of June 30, 2022 |
|  | Contingent Consideration at Purchase Date |  |  | Changes in Fair Value |  |  | Fair Value |  |  | Contingent Consideration |
Level 3: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, current - S5D |  | $ | 2,060,300 |  |  | $ | (662,700 | ) |  | $ | 1,397,600 |  |  | $ | 1,397,600 |
Contingent consideration, current - AUGGD |  |  | - |  |  |  | 568,571 |  |  |  | 568,571 |  |  |  | 568,571 |
Total contingent consideration, current |  | $ | 2,060,300 |  |  | $ | (94,129 | ) |  | $ | 1,966,171 |  |  | $ | 1,966,171 |
Level 3: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration, non-current - S5D |  | $ | 7,108,900 |  |  | $ | (1,768,100 | ) |  | $ | 5,340,800 |  |  | $ | 5,340,800 |

X
- Definition Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of cash, cash equivalents, and investments. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration